Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$107.00 USD

107.00
4,386,467

-1.70 (-1.56%)

Updated Oct 21, 2024 02:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic

Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.

Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20

Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

Stock Market News for Jun 8, 2021

Benchmarks closed mixed on Monday as investors waited for more economic data to determine the course of economic recovery

Merck (MRK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Merck (MRK) closed at $72.80, marking a -1.77% move from the previous day.

Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity

Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.

Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?

Smart Beta ETF report for RODM

Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma

The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer

Nilanjan Choudhury headshot

Oil & Gas Stock Roundup: BP & Eni's Angola Plans, Shell's Philippine Sale & More

Apart from BP (BP)-Eni (E) and Royal Dutch Shell (RDS.A), there were news from TOTAL (TOT), Equinor (EQNR) and The Williams Companies (WMB) during the week.

Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer

The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.

Bristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP Opinion

Bristol Myers' (BMY) Opdivo in combination with Yervoy gets positive CHMP recommendation by the EMA for an additional indication.

TOTAL (TOT) Signs 10-Year Deal With Merck to Sell Clean Power

TOTAL (TOT) signs a 10-year deal with Merck to sell clean energy to the latter. TOTAL is working to scale up renewable energy generation capability by adding new wind and solar assets.

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

Bristol Myers (BMY) Gets FDA Nod for Another Opdivo Indication

Bristol Myers (BMY) gets FDA approval for Opdivo (injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer.

Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials

Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.

The Zacks Analyst Blog Highlights: JPMorgan, Home Depot, Merck, T-Mobile US and Twilio

The Zacks Analyst Blog Highlights: JPMorgan, Home Depot, Merck, T-Mobile US and Twilio

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $78.41, marking a +0.81% move from the previous day.

Sheraz Mian headshot

Top Research Reports for JPMorgan, Home Depot & Merck

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), The Home Depot (HD), and Merck (MRK).

Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View

Moderna (MRNA) reports first profitable quarter on the back of its success with COVID-19 vaccine. The number of COVID-19 vaccine doses delivered in the first quarter add up to 102 million.

Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.

Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus

Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.